NCT02869295 2021-07-29
NKTR-214
Nektar Therapeutics
Phase 1/2 Completed
Clinical Trials
16 trialsNCT00003713 2018-08-29
Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors
Sanofi
Phase 1 Completed
NCT00003822 2018-08-29
SR-45023A in Treating Patients With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT00004049 2018-08-29
SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Sanofi
Phase 1 Completed
NCT00004927 2017-01-30
BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
R-Pharm
Phase 1 Completed
NCT01418677 2016-05-17
An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function
Eisai Inc.
Phase 1 Completed
NCT00607724 2015-10-08
GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT01560325 2015-09-16
Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers
Chong Kun Dang Pharmaceutical
Phase 1 Completed
NCT00550927 2013-05-15
Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00003403 2013-04-23
GPX-100 in Treating Patients With Solid Tumors
Gem Pharmaceuticals
Phase 1 Completed
NCT00349167 2012-11-30
PR-104 in Treating Patients With Advanced Solid Tumors
Proacta, Incorporated
Phase 1 Completed
NCT00077077 2012-05-16
DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Phase 1 Completed
NCT01028859 2011-12-22
Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers
Chong Kun Dang Pharmaceutical
Phase 1 Completed
NCT00616213 2011-06-01
PR104 and G-CSF in Treating Patients With Solid Tumors
Proacta, Incorporated
Phase 1 Completed
NCT01358227 2011-05-24
A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors
Proacta, Incorporated
Phase 1 Completed
NCT00459836 2011-03-02
PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors
Proacta, Incorporated
Phase 1 Completed